RxDoctor Payments Data

Timothy Chang, MD

MOHS-Micrographic Surgery · la Jolla, CANPI 1962766337

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.

$9,106in general payments, 2019–2025

Across 438 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$773
  • Sun Pharmaceutical Industries Inc.$575
  • LEO Pharma Inc.$511
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$8,66195%
  • Education$4455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,106 in reported general payments places this provider in the 85th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California

Medicare billing

Part B allowed, 2024
$1,082,076
Medicare patients
698
Services billed
7,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab12$79,376
Tacrolimus23$4,006
Fluorouracil38$2,313
Clobetasol Propionate39$1,485
Clindamycin Phosphate39$1,356
Doxycycline Hyclate95$1,140
Ketoconazole71$1,136
Fluocinonide17$493
Mupirocin63$454
Metronidazole14$453
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$298
Ciclopirox11$276
Triamcinolone Acetonide32$261
Hydrocortisone23$136

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →